Acelyrin Adopts Poison Pill
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable only if any person acquires 10% or more of Acelyrin's outstanding common stock.
Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...
With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...
Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback